Skip to main content

Idiopathic Multicentric Castleman's Disease

2
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Small Molecule
150%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
2
BortezomibPhase 21 trial
ZanubrutinibPhase 2Small Molecule1 trial
Active Trials
NCT03982771Unknown30Est. Jan 2023
NCT04743687Unknown30Est. Jan 2025
Recordati
RecordatiFrance - Saint-Victor
2 programs
Research questionsN/A1 trial
SiltuximabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT05995834Unknown100Est. Dec 2024
NCT04838860Terminated22Est. Apr 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
RecordatiSiltuximab
UNION therapeuticsZanubrutinib
UNION therapeuticsBortezomib
RecordatiResearch questions

Clinical Trials (4)

Total enrollment: 182 patients across 4 trials

NCT04838860RecordatiSiltuximab

Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

Start: Mar 2021Est. completion: Apr 202122 patients
Phase 2Terminated
NCT04743687UNION therapeuticsZanubrutinib

Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial

Start: Jan 2021Est. completion: Jan 202530 patients
Phase 2Unknown
NCT03982771UNION therapeuticsBortezomib

BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)

Start: Jan 2019Est. completion: Jan 202330 patients
Phase 2Unknown
NCT05995834RecordatiResearch questions

Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS)

Start: Oct 2023Est. completion: Dec 2024100 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.